Home » Posts tagged with » Eli Lilly and Company
Lilly wraps up acquisition of gene therapy company Prevail Therapeutics

Lilly wraps up acquisition of gene therapy company Prevail Therapeutics

Eli Lilly and Company (Lilly) has completed its previously announced deal worth up to $1.04 billion of US gene therapy company Prevail Therapeutics. The US pharma giant said that the deal gives it a new modality for drug discovery and development. Furthermore, it will extend its research efforts via the creation of a gene therapy […]

Lilly to launch pragmatic study of Covid-19 drug candidate bamlanivimab in New Mexico

Eli Lilly and Company (Lilly) has revealed plans to launch a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with Covid-19, in partnership with major local institutions in New Mexico. The US pharma giant said that carrying out the study in New Mexico will help in the collection of data on the effectiveness and […]

Continue reading …
Lilly to acquire US gene therapy company Prevail Therapeutics in $1bn deal

Eli Lilly and Company (Lilly) has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a US gene therapy company engaged in developing disease-modifying AAV9-based gene therapies for neurodegenerative diseases. According to the US pharma giant, the acquisition will set up a new modality for drug discovery and development. It will also […]

Continue reading …
Bamlanivimab Covid-19 drug candidate : Lilly, UnitedHealth Group join forces for pragmatic study

Eli Lilly and Company (Lilly) has entered into a partnership with managed care company UnitedHealth Group to carry out a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, Covid-19 infected individuals. Recently, bamlanivimab was granted emergency use authorization (EUA) from the US Food and Drug Administration for the treatment of Covid-19 patients having mild to moderate […]

Continue reading …
Lilly’s Covid-19 candidate bamlanivimab gets FDA’s EUA

The US Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg, the investigational neutralizing antibody of Eli Lilly and Company (Lilly) for the treatment of mild to moderate Covid-19. Bamlanivimab has been authorized to be used in adults and pediatric patients, aged 12 years and older with a […]

Continue reading …
Lilly signs $375m deal to supply Covid-19 candidate bamlanivimab to US govt

Eli Lilly and Company (Lilly) has signed a $375 million deal with the US government for the supply of 300,000 vials of bamlanivimab (LY-CoV555) 700mg, an investigational neutralizing antibody for the treatment of Covid-19. LY-CoV555 is the first antibody candidate to come out from Lilly’s collaboration with AbCellera Biologics, which was announced in March this […]

Continue reading …
Lilly to acquire SARM1 inhibitor developer Disarm Therapeutics

Lilly acquisition of Disarm Therapeutics : Eli Lilly and Company (Lilly) has agreed to acquire Disarm Therapeutics, a biotech company based in Cambridge, Massachusetts, which is focused on developing a new class of disease-modifying treatments for patients with axonal degeneration. As per the terms of the deal, Lilly will pay an upfront payment of $135 […]

Continue reading …
Lilly, Amgen collaborate to boost supply of potential COVID-19 therapies

Eli Lilly and Company has entered into a global antibody manufacturing collaboration with Amgen to considerably boost the supply capacity for its potential COVID-19 therapies. Currently, Lilly is studying various potential neutralizing antibodies for the prevention and/or treatment of the novel coronavirus as monotherapy or in combination. Through the collaboration, the two US pharma companies […]

Continue reading …
Reyvow CENTURION trial results : Lilly migraine drug succeeds in phase 3 study

Reyvow CENTURION trial results : Eli Lilly and Company (Lilly) said that its migraine drug Reyvow (lasmiditan) has met the co-primary endpoint of a phase 3 clinical trial called CENTURION by delivering pain freedom from migraine attacks at 60 minutes and up to 48 hours. According to the US pharma giant, adults who were given Reyvow […]

Continue reading …
Lilly, Innovent Biologics expand licensing deal for blood cancer drug Tyvyt

Eli Lilly and Company has signed an expanded licensing deal worth up to $1 billion with Chinese biotech company Innovent Biologics for their jointly developed Tyvyt (sintilimab injection), an approved blood cancer drug in China. The expanded deal gives the US pharma giant the rights to Tyvyt or geographies outside of China. Innovent Biologics and […]

Continue reading …
Page 1 of 3123